Picture of Viatris logo

VTRS Viatris News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapSuper Stock

REG - HealthBeacon PLC HealthBeacon - HBCN - 26% Adherence Improvement using HealthBeacon Tech

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220221:nRSU2086Ca&default-theme=true

RNS Number : 2086C  HealthBeacon PLC  21 February 2022

Peer Review validates the impact of HealthBeacon's Injection Care Management
System

Research shows 26% improvement in medication adherence with HealthBeacon
technology

 

HealthBeacon plc ("HealthBeacon" or the "Company"), the leading Irish digital
therapeutics company, is pleased to announce that new peer reviewed evidence
demonstrates a 26% improvement in medication adherence by patients using the
Company's Injection Care Management System (ICMS).

The results of HealthBeacon's latest study, published in the prestigious
International Journal of Clinical Pharmacy, proves the significant impact the
Company's ICMS can have on medication adherence for patients across a range
chronic, autoimmune conditions.

HealthBeacon's ICMS tracks adherence and persistence with medication schedules
through the provision of medication management reminders, safe and sustainable
sharps disposal devices, educational tools, and artificial intelligence driven
data analytics.

This Medication Adherence study represents the Company's 6(th) peer reviewed
study of Injection Care Management and Adherence. HealthBeacon's previous
publications include studies on Medication Persistence, Medication Adherence
Prediction, Digital Health Technology Adoption, Adherence to Injectable Growth
Hormone and Virtual Injection Training.

On April 7(th) HealthBeacon's data and medical team will be hosting a webinar
and presenting its full portfolio of peer reviewed publications for the
clinical community and healthcare organisations across Europe, UK and the USA
that are looking to improve patient support and engagement for patients on
self-administered injectable medications. To register for the event, go to
www.healthbeacon.com/webinars

Jim Joyce, CEO, and co-founder of HealthBeacon, commented: "It is well
documented that approximately one in every two of patients fail to adhere to a
specified regimen when long-term medication is prescribed. Medication
non-adherence is a serious problem which affects both patients and healthcare
systems, resulting in disease, death, and costs. HealthBeacon's technology
offers a solution to some of these issues through the world's first
FDA-cleared Smart Sharps Bin that is clinically proven to materially enhance
medication adherence. HealthBeacon's technology and services supports patients
and enhances their likelihood of success on important medications."

Dr. Sharifah Sarhan, MB BAO BCh, Medical Science Liaison at HealthBeacon,
added: "This latest published research by the International Journal of
Clinical Pharmacy adds to the growing portfolio of evidence demonstrating
HealthBeacon's ability to have a tangible benefit on patient medication
compliance. HealthBeacon's innovative technology is not only seeking to reduce
the burden of care on millions of patients that depend on injectable therapies
but is proving its ability to do so through real-world data and peer-reviewed
evidence."

HealthBeacon's growing customer base currently includes Amryt, Novartis, NHS,
HSE, Sanofi, Accord Healthcare, Clonmel Healthcare, Teva, Viatris, and AbbVie.

The Company remains focused on expanding its client base within pharmaceutical
companies, specialty pharmacy, healthcare organisations and governments as it
targets the deployment of 100,000 Smart Sharps Bin units by the end of 2023.

 Enquiries:
 HealthBeacon:                                   Investor.Relations@HealthBeacon.com

 Laurence Flavin

 Goodbody (Euronext Growth Adviser and Broker):  +353 (1) 667 0420

 David Kearney
 Stephen Kane

 Drury (Public Relations):
 Billy Murphy                                    +353 (0) 87 231 3085
 Cathal Barry                                    +353 (0) 87 227 9281

 

Ends

 

Notes

In this latest research on the benefits of HealthBeacon's technology,
published by the International Journal of Clinical Pharmacy, real world
adherence data was collected from almost 10,000 HealthBeacon patients and
compared to existing adherence data in literature.

The research results found that HealthBeacon's adherence was higher overall
for patients on therapy for a range of medical conditions. For HealthBeacon
patients on dermatological and gastroenterological treatments specifically,
adherence was 24% and 26% higher respectively than those without access to the
system. Furthermore, the proportion of those with 'optimal' adherence of 80%
or greater, was also higher amongst HealthBeacon groups. The study also
reported nearly identical adherence rates for males and females when using the
ICMS, helping to close a gender gap in previously reported adherence rates.

The International Journal of Clinical Pharmacy is a bimonthly peer-reviewed
medical journal covering all aspects of clinical pharmacy and related
practice-oriented subjects. The journal was established in 1965 and is
published by Springer Science+Business Media, a German multinational
publishing company of books, e-books and peer-reviewed journals in science,
humanities, technical and medical publishing.

The research on HealthBeacon's innovative technology was also presented at the
most recent ESPACOMP conference, the annual flagship symposium held by the
International Society for Medication Adherence.

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops products for managing injectable medications for patients in the
home. The Company operates in 17 countries primarily across Europe, North
America and the United Kingdom employs more than 50 people and has obtained
more than 30 design and utility patents. HealthBeacon's mission is to become
the world's leading digital therapeutics platform for injectable medications.

Ends

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISELBLLLLLLLBBD

Recent news on Viatris

See all news